Brain angiotensin II contributes to the development of hypertension in Dahl-Iwai salt-sensitive rats. 1995

H Teruya, and H Muratani, and S Takishita, and S Sesoko, and R Matayoshi, and K Fukiyama
Third Department of Internal Medicine, University of the Ryukyus School of Medicine, Okinawa, Japan.

OBJECTIVE To examine the role of brain angiotensin II in the development of salt-induced hypertension in Dahl-Iwai salt-sensitive (DIS) rats. METHODS Male DIS and Dahl-Iwai salt-resistant (DIR) rats aged 5 or 6 weeks were implanted with an intracerebroventricular cannula, and either chronic intracerebroventricular infusion of 5 micrograms/day CV-11974, a non-peptide type-1 angiotensin II receptor antagonist or artificial cerebrospinal fluid (aCSF) was started. The rats were fed a diet containing 8% sodium chloride. RESULTS On day 11 or 12 of chronic infusion, DIS rats given CV-11974 intracerebroventricularly exhibited a significantly lower mean arterial pressure than DIS rats given aCSF intracerebroventricularly or intravenous infusion of CV-11974. In DIR rats, intracerebroventricular infusion of CV-11974 did not alter the mean arterial pressure. Sodium and water balances were similar in all of the groups. Plasma vasopressin and noradrenaline levels did not differ among the groups, although the plasma renin concentration was significantly lower in DIS rats given aCSF intracerebroventricularly. Arterial baroreflex control of heart rate and pressor response to intravenous injection of phenylephrine were not altered in rats given CV-11974 intracerebroventricularly. CONCLUSIONS The integrity of the brain renin-angiotensin system is necessary for the development of salt-induced hypertension in DIS rats.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007276 Injections, Intraventricular Injections into the cerebral ventricles. Intraventricular Injections,Injection, Intraventricular,Intraventricular Injection
D008297 Male Males
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006728 Hormones Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. Hormone,Hormone Receptor Agonists,Agonists, Hormone Receptor,Receptor Agonists, Hormone
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

H Teruya, and H Muratani, and S Takishita, and S Sesoko, and R Matayoshi, and K Fukiyama
August 1995, Clinical and experimental hypertension (New York, N.Y. : 1993),
H Teruya, and H Muratani, and S Takishita, and S Sesoko, and R Matayoshi, and K Fukiyama
September 1991, Nihon Jinzo Gakkai shi,
H Teruya, and H Muratani, and S Takishita, and S Sesoko, and R Matayoshi, and K Fukiyama
January 1999, Journal of hypertension,
H Teruya, and H Muratani, and S Takishita, and S Sesoko, and R Matayoshi, and K Fukiyama
May 1997, American journal of hypertension,
H Teruya, and H Muratani, and S Takishita, and S Sesoko, and R Matayoshi, and K Fukiyama
January 1996, Hypertension (Dallas, Tex. : 1979),
H Teruya, and H Muratani, and S Takishita, and S Sesoko, and R Matayoshi, and K Fukiyama
May 1997, American journal of hypertension,
H Teruya, and H Muratani, and S Takishita, and S Sesoko, and R Matayoshi, and K Fukiyama
January 2010, Experimental physiology,
H Teruya, and H Muratani, and S Takishita, and S Sesoko, and R Matayoshi, and K Fukiyama
May 1997, American journal of hypertension,
H Teruya, and H Muratani, and S Takishita, and S Sesoko, and R Matayoshi, and K Fukiyama
January 1994, Life sciences,
H Teruya, and H Muratani, and S Takishita, and S Sesoko, and R Matayoshi, and K Fukiyama
October 1994, Laboratory animal science,
Copied contents to your clipboard!